The global market for DNA vaccines should grow from $3.1 billion in 2021 to $11.5 billion by 2026 with a compound annual growth rate (CAGR) of 30.1% for the period of 2021-2026.
DNA vaccines market for research tools should grow from $2.2 billion in 2021 to $8.7 billion by 2026 with a compound annual growth rate (CAGR) of 32.3% for the period of 2021-2026.
DNA vaccines market for clinical vaccines should grow from $924 million in 2021 to $2.8 billion by 2026 with a compound annual growth rate (CAGR) of 24.5% for the period of 2021-2026.
Report Scope
The study’s scope includes DNA vaccine products that already are commercialized or likely to be in the next five years. Both human and animal health markets are studied. DNA vaccine delivery technologies are also included. DNA vaccine candidates in clinical trials are examined by indication, and future market growth from 2021 through 2026 is forecast.
The role that DNA vaccines play in the overall vaccine industry is examined, as well as how the vaccine industry structure and dynamics are changing.
We examine DNA synthesis, biotechnology and pharmaceuticals firms, strategic industry alliances, and the role of gene delivery and synthesis technologies. The major markets for DNA vaccines, including infectious diseases, cancers, animal health, allergies and biodefense, are analyzed, and the main companies in these fields are highlighted.
The Report Includes
- 14 data tables and 55 additional tables
- An overview of the global market for DNA vaccines and related technologies
- Analyses of global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Coverage of delivery and synthesis technologies, the forces driving market growth, product formats, and market applications for these products
- Identification of new opportunities, challenges, and technological changes within the industry and highlights of the market potential for DNA vaccines by delivery technology, format, function and region
- Coverage of life cycle status and commercial status of DNA vaccine technologies and brief description of the Human Immune System
- Details about vaccines, their evolution, and types including DNA vaccines and cancer DNA vaccines, their function, scope and clinical trials, and information on changing vaccine paradigm, antigen discovery, plasmid design and manufacture and delivery technologies
- Detailed analysis of the current market trends, market forecast, and discussion of technological, and regulatory elements that are affecting the future marketplace
- Information about major technologies for the formulation of DNA vaccines and assessment of their relation to biotechnology, gene therapy, DNA delivery, pharmaceuticals, and biodefense companies
- Comprehensive profiles of leading companies in the field as well as updates to alliance, merger, and acquisition activities, including Astellas Pharma Inc., Bristol-Myers Squibb Co., Merck & Co., Novartis AG, Pfizer Inc. and Sanofi-Aventisa
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- What's New in This Update
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary
Chapter 3 Market Overview
- Introduction
- DNA Vaccine Technologies Covered in This Report
- Global Market for DNA Vaccines
- Forces Driving DNA Vaccine Market Growth
- Life Cycle Status of DNA Vaccine Technologies
- Commercial Status of DNA Vaccine Technologies
- DNA Vaccine Industry
Chapter 4 DNA Vaccine Technologies
- Introduction
- Human Immune System
- Vaccines
- Evolution of Vaccines
- Types of Vaccines
- DNA Vaccines
- Changing Vaccine Paradigm
- Function and Scope of DNA Vaccines
- Cancer DNA Vaccines
- DNA Vaccine Technology Value Chain
- Antigen Discovery
- Plasmid Design
- Plasmid Manufacture
- Delivery Technologies
- Uncomplexed pDNA
- Electroporation
- Liposomes
- Gold Particles
- Nanoparticles
- Bacterial Ghosts
- Bacteriophages
- Viruses
- Targeting Technologies
- Adjuvant Technologies
- DNA Vaccine Technology Needs
Chapter 5 DNA Vaccine Applications
- Research Tool Applications
- Clinical Application
- Overview to DNA Vaccine Clinical Trials Process
- Summary of DNA Vaccine Clinical Trials
Chapter 6 DNA Vaccine Industry
- Vaccine Industry Structural Shifts
- Industry Structure
- DNA Vaccine Industry Competitors
- DNA Vaccine Commercial Value Chain
- DNA Vaccine Competitor Strategic Positioning
- Research & Development
Chapter 7 DNA Vaccine Markets
- Drivers of Growth
- DNA Vaccine Markets
- Market Forecasts
- DNA Vaccine Research Tool Markets
- DNA Vaccine Clinical Markets
- DNA Vaccine Market by Region
- Research Tools for DNA Vaccine Market by Region
- Clinical DNA Vaccine Market by Region
Chapter 8 Impact of COVID-19
- Vaccines, Treatments and Diagnostics
- Vaccines
- Therapeutics
- Economic Impact of COVID-19
Chapter 9 Company Profiles
- Astellas Pharma Inc.
- Astrazeneca Plc
- Bristol-Myers Squibb Co.
- Gilead Sciences Inc.
- Johnson & Johnson
- Merck & Co.
- Novartis Ag
- Pfizer Inc.
- Sanofi-Aventis
List of Tables
Summary Table: Global DNA Vaccine Market, by Type, Through 2026
Table A: Scope of Report
Table 1: Growth Drivers of DNA Vaccine Industry
Table 2: Life Cycle Stage of Vaccine Types
Table 3: Commercial Status of DNA Vaccines
Table 4: DNA Vaccines Industry Structure
Table 5: DNA Vaccine History
Table 6: Components of the Immune System
Table 7: Vaccine Types
Table 8: Technology Life Cycle Stage of Vaccine Types
Table 9: Changing Vaccine Production
Table 10: Advantages and Disadvantages of DNA Vaccines
Table 11: Emerging Competitive Landscape for DNA Vaccines
Table 12: Cancer Vaccine Types
Table 13: Technology Drivers for DNA Vaccine Value Chain
Table 14: Plasmid Design Objectives
Table 15: Ways to Optimize Mammalian Gene Expression in Plasmid DNA
Table 16: DNA Plasmid Quality Comparison
Table 17: Comparison of DNA Delivery Technologies
Table 18: Comparison of In Vivo Viral Vector Technologies
Table 19: DNA Vaccine Adjuvant Technologies
Table 20: Technology Needs for DNA Vaccines
Table 21: DNA Vaccine Development
Table 22: DNA Vaccine Preclinical Development Steps
Table 23: Summary of DNA Vaccine Clinical Phase I Trials, June 2021
Table 24: Summary of DNA Vaccine Clinical Phase II Trials, June 2021
Table 25: Summary of DNA Vaccine Clinical Phase III Trials, June 2021
Table 26: Summary of DNA Vaccine Clinical Phase IV Trials, June 2021
Table 27: Summary of DNA Vaccine Cancer Clinical Trials, June 2021
Table 28: Infectious Disease DNA Vaccine Clinical Trials, June 2021
Table 29: Comparison of the Regulation of Rare Diseases and Orphan Drugs Worldwide
Table 30: Structural Shifts in Vaccine Industry
Table 31: Vaccine Industry Structure: Traditional Vs. Emerging
Table 32: Comparison of Vaccines and Drugs
Table 33: DNA Vaccine Industry Competitors
Table 34: Large Pharma Vaccine Company Strategic Focus
Table 35: Integrated Biotechnology Company Strategic Focus
Table 36: Strategy Market Focus of Integrated Biotechnology Companies
Table 37: Strategic Focus of Specialized Biotechnology Companies
Table 38: Astellas Pharma Inc. Open Clinical Trials, June 2021
Table 39: Bavarian Nordic Open Clinical Trials, June 2021
Table 40: City of Hope Medical Center, National Cancer Institute (NCI) Open Clinical Trials, June 2021
Table 41: Glaxosmithkline Open Clinical Trials, June 2021
Table 42: Imperial College London Open Clinical Trials, June 2021
Table 43: Merck Sharp & Dohme Open Clinical Trials, June 2021
Table 44: National Institute of Allergy and Infectious Diseases (NIAID) Open Clinical Trials, June 2021
Table 45: National Taiwan University Hospital Open Clinical Trials, June 2021
Table 46: Sanofi Open Clinical Trials, June 2021
Table 47: Sidney Kimmel Comprehensive Cancer Center Open Clinical Trials, June 2021
Table 48: U.S. Army Medical Research Open Clinical Trials, June 2021
Table 49: University of Colorado Open Clinical Trials, June 2021
Table 50: University of Oxford Open Clinical Trials, June 2021
Table 51: Driving Forces of the DNA Vaccine Industry’s Growth
Table 52: Global Market for DNA Vaccines, by Type, Through 2026
Table 53: Global Market for DNA Vaccine Research Tools, by Application, Through 2026
Table 54: Global Market for Clinical DNA Vaccines, by End Use, Through 2026
Table 55: DNA Vaccine Allergy Market Opportunities
Table 56: Cause of Death, Worldwide, 2019 and 2030
Table 57: Global Market for Cancer Clinical DNA Vaccines, by Indication, Through 2026
Table 58: DNA Vaccine Cancer Market Opportunities
Table 59: Global Market for Infectious Disease Clinical DNA Vaccines, by Type, Through 2026
Table 60: Global Market for Animal Health Clinical DNA Vaccines, by Indication, Through 2026
Table 61: Global Market for Biodefense Clinical DNA Vaccines, by End User, Through 2026
Table 62: Global Market for Clinical DNA Vaccines, by Delivery Technology, Through 2026
Table 63: Global Market for Clinical DNA Vaccines, by Vaccine Format, Through 2026
Table 64: Global Market for Clinical DNA Vaccines, by Vaccine Function, Through 2026
Table 65: Global Market for DNA Vaccines, by Region, Through 2026
Table 66: Global Market for Research Tools for DNA Vaccines, by Region, Through 2026
Table 67: Global Market for Clinical DNA Vaccines, by Region, Through 2026
Table 68: COVID-19 Global Impact on Public Health (as of June 2021)
List of Figures
Summary Figure: Global DNA Vaccine Market, by Type, 2019-2026
Figure 1: Evolution of Vaccine Technologies
Figure 2: Mechanism of Action of a DNA Vaccine
Figure 3: Safety and Efficacy Profile of DNA Vs. Viral-Vector Vaccines
Figure 4: DNA Vaccine Function and Market Scope
Figure 5: DNA Vaccine Technology Value Chain
Figure 6: Conventional and Plasmid DNA Vaccine Production Process
Figure 7: Schematic of EP Process
Figure 8: Strategies for Targeting Dendritic Cells
Figure 9: Overview of Future Vaccine Clinical Trials
Figure 10: Summary of DNA Vaccine Clinical Trials
Figure 11: DNA Vaccine Clinical Phases from 2005 to 2021
Figure 12: DNA Vaccine Commercial Value Chain
Figure 13: DNA Vaccine Strategic Market Grid
Figure 14: Pipeline of COVID-19 Vaccines, by R&D Stage
Figure 15: Pipeline of COVID-19 Therapeutics, by R&D Stage
Figure 16: Estimates of Economic Impact of COVID 19 and Recovery Forecasts
Samples
LOADING...
Executive Summary
Vaccines, once a stable though unexciting sector of the pharmaceutical industry, are becoming an attractive growth opportunity. DNA vaccines are an emerging vaccine platform within this changing paradigm. DNA vaccines target a wide range of traditional pharmaceutical markets, such as cancers and allergies, as well as infectious diseases. The vaccine industry has proved that it can generate products with nontraditional applications and blockbuster potential. Products such as that from ViroCyt, now part of Sartorius Stedim Biotech, are leading the field of rapid virus quantification. DNA vaccines are poised to generate significant future market potential.
New biotechnologies and nanotechnologies are driving DNA vaccine development. Particularly key to DNA vaccines reaching their potential are emerging delivery technologies such as electroporation (EP), innovative vaccine formats such as DNA prime-adenovector boost, and novel molecular adjuvant technologies. These technologies are providing the means for achieving the higher efficacy in humans that is required for the commercialization of DNA vaccines.
DNA vaccines have already made significant progress to date. There are three approved DNA vaccines for animal health applications and nearly 100 clinical trials underway in humans for a wide range of diseases. There is a deep pipeline of preclinical projects. A small but strategic market segment is commercial today, consisting of research tools and animal health applications.
The high growth is the result of a low starting base and a forecast introduction of several DNA vaccines late in the period. While research tools and animal health clinical applications currently dominate the market, human clinical DNA vaccines will make up the vast majority of this market through 2026.
Companies Mentioned
- Astellas Pharma Inc.
- Astrazeneca Plc
- Bristol-Myers Squibb Co.
- Gilead Sciences Inc.
- Johnson & Johnson
- Merck & Co.
- Novartis Ag
- Pfizer Inc.
- Sanofi-Aventis
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 113 |
| Published | August 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 3.1 Billion |
| Forecasted Market Value ( USD | $ 11.5 Billion |
| Compound Annual Growth Rate | 30.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
